Home/Pipeline/REM392 (Alzheimer's Program)

REM392 (Alzheimer's Program)

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

reMYND

About reMYND

reMYND is a private, clinical-stage biotech developing novel oral therapeutics targeting synaptic and neuronal dysfunction in Alzheimer's and Huntington's disease. Its lead asset, REM392, is an oral small molecule designed to restore calcium homeostasis to provide both symptomatic and disease-modifying benefits in Alzheimer's. The company leverages a dual-strategy business model, combining internal drug development with a revenue-generating CRO service that validates its scientific platform and funds R&D.

View full company profile

Therapeutic Areas

Alzheimer's Disease Huntington's Disease Amyotrophic Lateral Sclerosis (ALS)

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active